Federal Register of Legislation - Australian Government

Primary content

PB 63 of 2019 Determinations/Health as made
This instrument amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) by adding one drug to F1 and moving another drug from F1 to the single brand Combination Drug List (CDL). It also determines that two drugs are changing formulary status from F1 to F2 with another drug on the CDL also moving to F2 with the listing of new brands. In addition, one drug is delisting off the Pharmaceutical Benefits Scheme and is required to be removed from F1.
Administered by: Health
Registered 30 Jul 2019
Tabling HistoryDate
Tabled HR30-Jul-2019
Tabled Senate31-Jul-2019
To be repealed 13 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

 

PB 63 of 2019

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated             26   July 2019

 

 

 

 

 

 

 

 

 

THEA DANIEL

 

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 7).

         (2)   This Determination may also be cited as PB 63 of 2019.

2              Commencement

                This Determination commences on 1 August 2019.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

[1]     Schedule 1, after item dealing with Apraclonidine

 

Omit

Aprepitant

 

[2]     Schedule 1, after item dealing with Flupentixol decanoate

 

Omit

Fluticasone furoate with vilanterol

Insert

Fluticasone furoate

 

[3]     Schedule 1, after item dealing with Hydrochlorothiazide

 

Omit

Hydromorphone

 

[4]     Schedule 1, after item dealing with Tranylcypromine

 

Omit

Trastuzumab

 

[5]     Schedule 2, after item dealing with Hydrocortisone

 

Insert

Hydromorphone

 

[6]     Schedule 2, after item dealing with Tenofovir with emtricitabine

 

Insert

Tenofovir with emtricitabine and efavirenz

 

[7]     Schedule 2, after item dealing with Tranexamic acid

 

Insert

Trastuzumab